AtriCure, Inc. ATRC R2KR3KPHARMA
Company Overview
AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. It offers Isolator Synergy Ablation System clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. It also provides cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; cryoXT probes, a cryoablation device designed specifically for Cryo Nerve Block therapy; LARIAT System, a solution for soft-tissue closure; Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; and Subtle Cannula's to support access for EPi-Sense catheters. In addition, the company sells various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
Why Investors Should Care
Revenue has grown at a 16.4% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.14.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $534.53M (+14.9% YoY).
- Trailing 12 Months Year-on-year growth — revenue +12.8%.
- 5-Year Trend Long-term compounding — revenue CAGR 16.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 16.44% |
| 1 Year: | 12.80% |
Stock Price Performance
| 1 Year: | +40.38% |
| 6 Months: | +71.62% |
| 3 Months: | +90.11% |
| 1 Month: | +30.46% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)74.17 · Overbought
P/E of 245.33 is above the sector median of 25.17 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 16.4% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading at a high P/E of 245.3.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ATRC AtriCure, Inc. R2KR3KPHARMA | 51.52 | 245.33 | $2.62B | 0.00% | -1.65% | 2.15% | 16.44% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | 42.15M | - | 46.99M | 51.80M | 49.94M | 52.89M | 53.97M | 58.91M | 56.61M | 61.32M | 53.23M | 40.82M | 54.76M | 57.73M | 59.27M | 71.38M | 70.46M | 73.22M | 74.58M | 84.53M | 83.25M | 93.49M | 100.92M | 98.29M | 108.85M | 116.27M | 115.91M | - | 123.62M | 136.14M | 134.27M | 140.50M | 141.25M | 153.60M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 30.99M | 34.66M | 32.94M | 35.16M | 31.94M | - |
| Gross Profit | 25.91M | 28.82M | 27.47M | 28.90M | 30.01M | 32.55M | 30.92M | 32.68M | 34.50M | 38.08M | 35.95M | 38.59M | 39.87M | 43.89M | 41.80M | 44.77M | 38.88M | 27.65M | 40.33M | 42.44M | 44.54M | 54.08M | 52.23M | - | 55.59M | 63.52M | 61.71M | 69.61M | 77.08M | 73.87M | 81.27M | 86.84M | 86.79M | - | 92.63M | 101.48M | 101.33M | 105.34M | 109.31M | 118.63M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 98.58M | 107.67M | 101.12M | 102.85M | 108.78M | - |
| Operating Income | -9.42M | -7.74M | -6.29M | -7.70M | -9.64M | -6.36M | -6.85M | -2.13M | -9.43M | 958.00K | -6.05M | -2.61M | -5.32M | -3.84M | -8.64M | -15.33M | -15.45M | -7.29M | -3.99M | -17.50M | -15.88M | -15.08M | 98.67M | - | -14.15M | -13.66M | -10.72M | -5.78M | -4.14M | -8.09M | -10.92M | -7.17M | -7.41M | - | -5.95M | -6.19M | 208.00K | 2.49M | 526.00K | 9.66M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -8.00K | 732.00K | 6.55M | 8.97M | 7.01M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.42M | 1.49M | 1.47M | 1.50M | 1.34M | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -6.51M | -5.93M | -86.00K | 2.36M | 394.00K | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 239.00K | 261.00K | 181.00K | 604.00K | 286.00K | - |
| Net Income | -9.72M | -8.21M | -6.78M | -8.62M | -10.18M | -6.88M | -7.25M | -2.58M | -10.13M | -338.00K | -7.24M | -3.43M | -5.63M | -4.10M | -9.36M | -16.10M | -16.41M | -8.24M | -4.95M | -18.56M | -16.92M | -16.25M | 97.11M | - | -15.18M | -14.84M | -12.27M | -6.48M | -5.12M | -9.05M | -13.27M | -8.01M | -7.85M | - | -6.75M | -6.19M | -267.00K | 1.76M | 108.00K | 8.96M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.11 | - | -0.38 | -0.36 | 2.11 | - | -0.33 | -0.32 | -0.27 | -0.14 | -0.11 | -0.20 | -0.28 | -0.17 | -0.17 | - | -0.14 | -0.13 | -0.01 | 0.04 | 0.00 | 0.18 |
| R&D Expense | 8.56M | 9.12M | 8.27M | - | 9.55M | 8.91M | 7.97M | - | 9.06M | 8.65M | 8.56M | - | 8.18M | 9.80M | 10.15M | - | 11.59M | 10.04M | 10.58M | - | 11.22M | 12.20M | 11.28M | - | 13.63M | 14.79M | 15.17M | 15.33M | 17.44M | 20.35M | 19.84M | 20.42M | 20.96M | - | 22.53M | 29.28M | 22.89M | - | 24.23M | 26.40M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 54.53M | 59.01M | 64.40M | 70.25M | 81.89M | 107.45M | 129.75M | 155.11M | 174.72M | 201.63M | 230.81M | 206.53M | - | 330.38M | 399.25M | 465.31M | 534.53M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 84.44M | 98.88M | 117.78M | 133.75M |
| Gross Profit | 41.78M | 45.39M | 47.00M | 50.01M | 59.56M | 75.75M | 92.88M | 111.10M | 126.16M | 147.12M | 170.34M | 149.31M | - | 245.94M | 300.37M | 347.52M | 400.78M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 288.61M | 327.05M | 387.54M | 410.23M |
| Operating Income | -15.51M | -3.19M | -4.73M | -7.20M | -10.89M | -16.36M | -26.72M | -31.14M | -24.98M | -17.13M | -33.12M | -44.23M | - | -42.67M | -26.68M | -40.01M | -9.45M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | -29.50M | -8.11M | -18.53M | 16.25M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.99M | 6.92M | 6.41M | 5.88M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | -46.20M | -29.85M | -43.67M | -10.16M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | 268.00K | 591.00K | 1.02M | 1.28M |
| Net Income | -16.49M | -3.79M | -5.46M | -7.53M | -11.46M | -16.21M | -27.21M | -33.34M | -26.89M | -21.14M | -35.19M | -48.16M | 50.20M | -46.47M | -30.44M | -44.70M | - |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | -0.94 | -1.14 | - | -1.02 | -0.66 | -0.95 | -0.24 |
| R&D Expense | 11.41M | 11.53M | 11.86M | 12.15M | 13.44M | 18.60M | 25.74M | 35.82M | 34.14M | 34.72M | 41.23M | 43.07M | 48.51M | 57.34M | 73.92M | 96.18M | 99.21M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Jan 2024 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 33.72M | 33.86M | 32.43M | 111.95M | 158.40M | 273.09M | 276.42M | 267.70M | 356.76M | 557.88M | 714.54M | - | 585.45M | 613.93M | - | 609.33M | 654.18M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 215.21M | 266.25M | - | 267.83M | 322.52M |
| Cash & Equivalents | 11.45M | 8.90M | 4.23M | 9.76M | 7.75M | 14.89M | 28.38M | 23.76M | 24.21M | 21.81M | 32.23M | 28.48M | 41.94M | - | 58.10M | 84.31M | - | 122.72M | 167.43M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 45.93M | 67.90M | - | 75.33M | 78.49M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 42.69M | 52.50M | - | 60.34M | 66.65M |
| Total Liabilities | - | - | 16.98M | 18.24M | 19.93M | 39.34M | 25.87M | 86.41M | 107.98M | 106.54M | 107.38M | 310.54M | 302.14M | - | 128.69M | 147.76M | - | 148.36M | 162.24M |
| Current Liabilities | - | - | 13.04M | 10.81M | 12.21M | 26.71M | 25.64M | 31.59M | 28.83M | 31.90M | 40.22M | 49.92M | 49.14M | - | 58.39M | 74.57M | - | 73.42M | 81.52M |
| Long Term Debt | - | - | - | - | - | - | - | - | 23.89M | 24.10M | 35.57M | 59.63M | 53.44M | - | 56.83M | 60.59M | 61.00M | 61.87M | 61.87M |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 74.55M | 74.49M | - | 73.72M | 73.38M |
| Total Equity | 29.12M | 17.09M | 16.74M | 15.62M | 12.50M | 72.60M | 132.54M | 186.69M | 168.44M | 161.17M | 249.38M | 247.34M | 412.39M | - | 456.75M | 466.17M | - | 460.97M | 491.94M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 46.56M | 47.53M | - | 48.87M | 49.79M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 419.95K | -33.00K | -1.99M | -1.94M | -5.22M | - | -7.84M | -15.12M | -8.94M | -4.17M | -15.81M | -19.87M | - | -22.14M | 4.48M | 12.20M | 57.33M |
| Investing Cash Flow | -2.17M | -3.33M | 2.72M | -2.80M | -14.15M | - | -10.50M | -12.08M | 3.76M | -85.40M | -2.15M | -156.20M | - | 44.01M | 21.82M | 30.23M | -14.55M |
| Financing Cash Flow | -914.01K | -1.44M | 4.85M | 2.66M | 26.83M | - | 13.96M | 27.70M | 2.76M | 100.18M | 14.37M | 189.39M | - | -7.06M | -32.00K | -3.60M | 1.18M |
| Capital Expenditure | -1.36M | -1.81M | -1.52M | -2.98M | -2.86M | -5.51M | -13.45M | -7.69M | -6.38M | -6.21M | -12.18M | -5.26M | - | -16.88M | -42.00M | -23.46M | -15.05M |
| Free Cash Flow | -940.51K | -1.85M | -3.51M | -4.92M | -8.09M | - | -21.29M | -22.81M | -15.33M | -10.38M | -27.99M | -25.13M | - | -39.02M | -37.51M | -11.26M | 42.28M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | - | 14.81M | 26.27M | 38.84M | 43.96M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 76.6% | 76.9% | 73.0% | 71.2% | 72.7% | 70.5% | 71.6% | 71.6% | 72.2% | 73.0% | 73.8% | 72.3% | - | 74.4% | 75.2% | 74.7% | 75.0% |
| Operating Margin % | -28.4% | -5.4% | -7.3% | -10.2% | -13.3% | -15.2% | -20.6% | -20.1% | -14.3% | -8.5% | -14.4% | -21.4% | - | -12.9% | -6.7% | -8.6% | -1.8% |
| Net Margin % | -30.2% | -6.4% | -8.5% | -10.7% | -14.0% | -15.1% | -21.0% | -21.5% | -15.4% | -10.5% | -15.2% | -23.3% | - | -14.1% | -7.6% | -9.6% | - |
| ROE % | -96.5% | -22.7% | -34.9% | -60.3% | -15.8% | -12.2% | -14.6% | -19.8% | -16.7% | -8.5% | -14.2% | -11.7% | - | -10.2% | -6.5% | -9.7% | - |
| ROCE % | - | -15.4% | -20.5% | -35.6% | -12.8% | -12.3% | -11.1% | -12.6% | -10.6% | -5.4% | -6.5% | -6.6% | - | -8.1% | -4.9% | -7.5% | -1.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 8.80% | 4.47M | $217.19M |
| 2 | Wellington Management Group, LLP | 6.87% | 3.50M | $169.68M |
| 3 | Vanguard Portfolio Management LLC | 6.15% | 3.13M | $151.79M |
| 4 | Hood River Capital Management LLC | 5.71% | 2.91M | $141.02M |
| 5 | Alliancebernstein L.P. | 5.44% | 2.77M | $134.38M |
| 6 | Vanguard Capital Management LLC | 4.31% | 2.19M | $106.32M |
| 7 | Nomura Asset Management International Inc | 3.41% | 1.73M | $84.18M |
| 8 | Goldman Sachs Group Inc | 3.14% | 1.60M | $77.57M |
| 9 | State Street Corporation | 2.73% | 1.39M | $67.47M |
| 10 | Marshall Wace LLP | 2.62% | 1.33M | $64.75M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ATRC
Insider Sale: Chief Technical Officer of $ATRC Sells 7,763 Shares - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxPOXlHbVNtd01CTGVtcU16MzAtMnZZR1VNcG1PREhCcm1ZanRvaW80NmZ5OWR5d1lQajdZVUhFMmMxemQtS2lFSFZpSjF3RnZzeXhCWWFsUUdFQVFkLTVMVG0wc29ORUx5RGFreDN0ckIwdEJ5WHJBQTZJMTh0ZDRFdjBIMTdOUjVJVGQtOH…
Insider Sale: Chief Technical Officer of $ATRC Sells 7,763 Shares - Moomoo
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxOVnVMb0dZZV9yZDIxLUw0Nmt2UlFqR2hua2QyYmUteUU2bDBTcE1lZUctdENKQk51anRtalI0OGZUUTVuZDd6SEY5dGdGWkZ1bDJQR1VNc1RKb0xHYjQxdDJRZkFReGN2R3FEU0N1aUlKNlpZdDRkdEY2UWZKVTM5ejEzV1BkVlU2Qy04VE…
AtriCure (ATRC) Stock May Be Fairly Valued On Its Growth Outlook - simplywall.st
<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxOLUgzaExZUDNwdDc0dU1tY3pjTHF3NnVEUEtQSzM1c0V4VGRhejNUUk5BczkwWmdJOUJVWkxMU0ZzX09yX1BUTXJRN2VXTHJoYnJhNmRaWDZFOHZNQWlyNkhyLU1SYmhUTGhnbDRGSER2NXh6RTh2VF9IaHRUQjF6S0Z4dzU4SkhHUXRCWm…
AtriCure, Inc. (ATRC) Beat Earnings Estimates. Here’s What Could Drive ATRC Stock Next - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxPVy1PdU1nR1EyUEQ1eUZVSmlDRWhGVWNLZFNVc3lXbGlsemhucXU4enZNOHctRnluYVdKMktWd19zaVhkS2dwTEdGODlMNk9Eb1VnQzRpcXZDdWJGd1pucnRQS0lBbzlzMHRFd2xVVl9RSWszbzI3Q1RnM0pHVm0tSFhCV3FjQTc4NTRfZH…
AtriCure (ATRC) CTO sells stock under preset plan - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxQRXBrSjdiNGZnV2lkNmd4ZFRMRmhaTlcwaThKN2JDREVlS3Atdzd0TlFvOXdNbEFVU0xkSzR0UC1lWWY4UnY5Ni1sZzJiU2lFdXgwN0NyTFNEcmIxa1czNktucDZDR2UzcVZUUEExRUI0azd2OXBBYjl1Sjh5Vi1TcTYtSDJScU01ZWVLeD…
Biotech Stocks At 52-Week Highs - ATTO, HALO, IKT, TVTX, ATRC - RTTNews
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxPMkxGWkhGc2Q2VGoyXzl2Y2o0VHB1dlBlV1EtbFVfb2lITnBEcU1OMEJFUF9hNERsOU1yN1BkS29YYi1Ic0lRa2RSZ0ozV1lrcU1OdkVWRVZfTTl1c0FiRzFXZTNRUWlaaG9LZ2lIcWNFbkpzWmVRcmpyTlJoVURPMVVxRjBUQ19QSV90N1…
ATRC — Frequently Asked Questions
What is the current share price of AtriCure, Inc. (ATRC)?
As of 2026-09-07 16:24 PDT, AtriCure, Inc. (ATRC) trades at $51.52 on NasdaqGM. Its 52-week range is $25.86 to $52.59.
What is the market capitalisation of ATRC?
AtriCure, Inc. (ATRC) has a market capitalisation of $2.62B on NasdaqGM.
What is the P/E ratio of ATRC?
ATRC trades at a trailing price-to-earnings (P/E) ratio of 245.33. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 4.08.
What is the return on equity (ROE) of ATRC?
ATRC has a return on equity (ROE) of 2.15%. Its return on capital employed (ROCE) is -1.65%.
Is ATRC a good stock to buy?
This page provides a data-driven analysis of AtriCure, Inc. (ATRC), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.